CA2004468C - Sustained release, comfort formulation for glaucoma therapy - Google Patents
Sustained release, comfort formulation for glaucoma therapyInfo
- Publication number
- CA2004468C CA2004468C CA002004468A CA2004468A CA2004468C CA 2004468 C CA2004468 C CA 2004468C CA 002004468 A CA002004468 A CA 002004468A CA 2004468 A CA2004468 A CA 2004468A CA 2004468 C CA2004468 C CA 2004468C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- composition according
- concentration
- exchange resin
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Abstract
Disclosed are nonstinging, sustained release ophthalmic formulations to control intraocular pressure in antiglaucoma therapy comprising a basic active, a cation exchange resin, and, inter alia, an acidic, mucomimetic polymer. Also disclosed are methods of treatment comprising administering such formulations topically to the eye when indicated for control and lowering for intraocular pressure.
Description
2(~0~68 SUSTAINED REIIEASE, CO~qFORT FORMULATIOM
FOR t~r ~TI~¢A THERAPY
Backqround of the Invention This invention relates to ophthalmic f ormulations useful in controlling and lowering intraocular pressure (IOP) in the treatment of glaucoma. The formulation3 of the present invention are characterized as long lasting ~sustained release) and are initlally and continually comfortable to the eye. Specifically, the invention relates to formulations of the above characteristics which comprise, inter alia, a basic active and cationic exchange resin (finely divided) dispersed in an aqueous solution or gel of ~n acidic, mucomimetic polymer. Such resulting aqueous gel or pourable liquid f ormulations are characterized by controlled cationic-anionic interactions, which appear to be responsible for the resulting comfort and sustained release properties. This invention also relates to methods of treatment which comprise administering the described compositions when indicated for treatiny ocular hypertension and glaucoma.
The term "basic active" means the active ingredient or ingredients in the disclosed formulations which have the desired effect on intraocular pressure and which bear, or are capable of bearing, a positive charge during f ormulation of the f inal product or as 25 fo= =lated in the final product form. Thus, the tesm basic, or cationic, active i8 descriptive for purposes of the disclosure and claims.
Such basic actives include all presently known beta blockers which demonstrate the requisite cationic 5 charge and IOP effect. Typically, such beta blockers are represented by the following generic structure, which structure also represents the beta blocker basic actives of the present disclosure:
R -o-CH2-CH(oH)-CH2-NR2R3 (I) 10 wherein: Rl is a substituted or unsubstituted cyclic or aliphatic moiety; cyclic moieties include mono- and polycyclic structures which may contain one or more heteroatoms selected from C, N, and O; R2 and R3 are independently selected from H and 8ubstituted and 15 unsubstLtuted alkyl . With regard to Structure ( I ), above, the following references are ~ereby made of record 2 Annual Re~orts in Mr~ r~ Chemist~ 14, 81-87 (1979); J. ~ed. Chem. 1983, 26,1570-1576; ibid..
1984, 27, 503-509; ibid., 1983, 26, 7-11; ibid., 1983, 26, 1561-1569; ibid., 1983 1109-1112; ibid., 1983, 26, 950-957; ibid., 1983, 26, 649-657; and ibid., ~, 26, 352-357. Representative of such basic actives are:
betaxolol, timolol, befunolol, labetalol, propranolol, bupranolol, metaprolol, bunalol, esmalol, pindolol, 25 carteolol, hepunolol, metiprAnolol, celiprolol, azotinolol (S-596), diacetolol, acebutolol, salbutamol, atenulol, isoxaprolol, and the like.
The def inition of ba~ic active also include3 the following classes of drug8 which are u3ed in treatment 30 of ocular hypertension and glaucoma: pilocarpine;
epinephrine; proepineph~ine; norepinephrine;
pronorepinephrine; clonidine; and clonidine ~ A ..
FOR t~r ~TI~¢A THERAPY
Backqround of the Invention This invention relates to ophthalmic f ormulations useful in controlling and lowering intraocular pressure (IOP) in the treatment of glaucoma. The formulation3 of the present invention are characterized as long lasting ~sustained release) and are initlally and continually comfortable to the eye. Specifically, the invention relates to formulations of the above characteristics which comprise, inter alia, a basic active and cationic exchange resin (finely divided) dispersed in an aqueous solution or gel of ~n acidic, mucomimetic polymer. Such resulting aqueous gel or pourable liquid f ormulations are characterized by controlled cationic-anionic interactions, which appear to be responsible for the resulting comfort and sustained release properties. This invention also relates to methods of treatment which comprise administering the described compositions when indicated for treatiny ocular hypertension and glaucoma.
The term "basic active" means the active ingredient or ingredients in the disclosed formulations which have the desired effect on intraocular pressure and which bear, or are capable of bearing, a positive charge during f ormulation of the f inal product or as 25 fo= =lated in the final product form. Thus, the tesm basic, or cationic, active i8 descriptive for purposes of the disclosure and claims.
Such basic actives include all presently known beta blockers which demonstrate the requisite cationic 5 charge and IOP effect. Typically, such beta blockers are represented by the following generic structure, which structure also represents the beta blocker basic actives of the present disclosure:
R -o-CH2-CH(oH)-CH2-NR2R3 (I) 10 wherein: Rl is a substituted or unsubstituted cyclic or aliphatic moiety; cyclic moieties include mono- and polycyclic structures which may contain one or more heteroatoms selected from C, N, and O; R2 and R3 are independently selected from H and 8ubstituted and 15 unsubstLtuted alkyl . With regard to Structure ( I ), above, the following references are ~ereby made of record 2 Annual Re~orts in Mr~ r~ Chemist~ 14, 81-87 (1979); J. ~ed. Chem. 1983, 26,1570-1576; ibid..
1984, 27, 503-509; ibid., 1983, 26, 7-11; ibid., 1983, 26, 1561-1569; ibid., 1983 1109-1112; ibid., 1983, 26, 950-957; ibid., 1983, 26, 649-657; and ibid., ~, 26, 352-357. Representative of such basic actives are:
betaxolol, timolol, befunolol, labetalol, propranolol, bupranolol, metaprolol, bunalol, esmalol, pindolol, 25 carteolol, hepunolol, metiprAnolol, celiprolol, azotinolol (S-596), diacetolol, acebutolol, salbutamol, atenulol, isoxaprolol, and the like.
The def inition of ba~ic active also include3 the following classes of drug8 which are u3ed in treatment 30 of ocular hypertension and glaucoma: pilocarpine;
epinephrine; proepineph~ine; norepinephrine;
pronorepinephrine; clonidine; and clonidine ~ A ..
3 2(:~04468 derivatives, for exampLe, p-aminorl nn~ nl~ and p-acetoamidor 1 nn i ~i ~ n =^ .
Thus, in summary, the basic active ~ t of the present invention is defined by its intraocular 5 pre6sure lowering effect or static control thereof, and by itfi cationic nature in an aqueous medium in the pH
range of from 3 . 0 to 8.5. The following patent publication6, which are herebv m~de of record f urther representatively demonstrate the 10 basic actives of the l?resent invention: U. 5 . Patents Nos. 4,252,984; 3,309,406; 3,619,370; 3,655,663;
3,657,237; 4,012,444; 3,663,607; 3,836,671; 3,857,952;
3,202,660; and 2,774,789.
Detailed Descri~tion of the Invention The ophthalmic formulations of the present invention are in the form of: anhydrous salts;
pourable, aqueous dispersions; and aqueous gels. The f ormulations comprise, in addition to conventional ingredients which provide, for example, bacterio~tatic 20 and formulatory balance functions, a critical polyanionic polymer, a cation exchange resin and the basic active of choice. Such anhydrous salt forms are incorporated into ointments or solid ocular inserts which form colloidal gels in situ on administration to 25 the eye . The pourable liquid and gel : ~-i i ts are applied topically to the eye. It should be noted that such liquid and gel ' ~ 8 can be obtained from the anhydrous form on formulation with water.
The f ormulations of the present invention 30 demonstrate sustained release of the basic active and are comfortable on topical administration to the eye.
It fihould be noted, in a general sense, that a stinging sensation re3ults when the basic actives, identif ied ,.
'~
Z~0~4~3 above, are administered neat. Thus, achieving both comf ort and sustained release is an unexpected result and permits administration of a class of ~, -jR that otherwise might not be considered.
Thus, in summary, the basic active ~ t of the present invention is defined by its intraocular 5 pre6sure lowering effect or static control thereof, and by itfi cationic nature in an aqueous medium in the pH
range of from 3 . 0 to 8.5. The following patent publication6, which are herebv m~de of record f urther representatively demonstrate the 10 basic actives of the l?resent invention: U. 5 . Patents Nos. 4,252,984; 3,309,406; 3,619,370; 3,655,663;
3,657,237; 4,012,444; 3,663,607; 3,836,671; 3,857,952;
3,202,660; and 2,774,789.
Detailed Descri~tion of the Invention The ophthalmic formulations of the present invention are in the form of: anhydrous salts;
pourable, aqueous dispersions; and aqueous gels. The f ormulations comprise, in addition to conventional ingredients which provide, for example, bacterio~tatic 20 and formulatory balance functions, a critical polyanionic polymer, a cation exchange resin and the basic active of choice. Such anhydrous salt forms are incorporated into ointments or solid ocular inserts which form colloidal gels in situ on administration to 25 the eye . The pourable liquid and gel : ~-i i ts are applied topically to the eye. It should be noted that such liquid and gel ' ~ 8 can be obtained from the anhydrous form on formulation with water.
The f ormulations of the present invention 30 demonstrate sustained release of the basic active and are comfortable on topical administration to the eye.
It fihould be noted, in a general sense, that a stinging sensation re3ults when the basic actives, identif ied ,.
'~
Z~0~4~3 above, are administered neat. Thus, achieving both comf ort and sustained release is an unexpected result and permits administration of a class of ~, -jR that otherwise might not be considered.
5 PolYanionic Polvmer Coml)onent The high molecular wQight, polyanionic polymers useful in the present invention have a molec~lar weight of from about 50,000 to about 6 million. The polymers are characterized as having carboxylic acid ~unctional 10 groups, and preferably contain from 2~to 7 carbon atoms per functional group. The gels which form during the preparatlon of the ophthalmic polymer dispersion have a viscosity of from about 1,000 to about 300,000 cps. In addition to the basic active-polymer (anionic-catonic) 15 interactions, mentioned above, the high molecular weight polymers used in the compositions of the present invention thicken the compositions to provide a gel, and provide a special type of rheology, i.e., plastic viscosity, which is translatable to the sustaLned 20 release and comfort of the final compositions. Such compositions range in pH from 3 . 0 to 8 . 5 .
The pourable liquid ' ' i ts ( administered as drops to the eye ) of the present invention have a viscosity of from about 1 to 20,000 cps. The pH
25 requirements are the same as recited above for the gel f inal products, i . e ., pH 3 . 0-8 . 5 .
The thLrd pharmaceutical form of the present invention, the anhydrous salt form, is derived from a salt of the polycarboxylic acid polymer and the basic 30 active. (The presence of the cationic ion exchange resin also contributes to salt formation; thQ nature of the ion exchange resin, in all ~ Ls of the present invention, is defLned below. ) Such salts can 2~0~468 be formulated, or reconstituted, to aqueous gels and pourable dispersions, a6 described above, on addition of water; or can be formulated as ocular inserts according to known technology and shapes; or they can 5 be combined with an oleaginous vehicle to f orm an ophthalmic ointment. All such final ophthalmic pharmaceutical forms are fully described below.
The term ' plastic viscosity", above, is indicative of a materi~ l that does not perceptibly f low until a 10 certain force or stress value is exceeded; this force or stress is ref erred to as the yield value . While not wishing to be bound by any theory, it i8 believed that the increased duration of activity of the compositions of the present invention is related, in part, to the 15 yield value. The compositions of the present invention exhibit a unique response to shear stress. When the yield value is t-~ r~ d~ the gel structure is altered temporarily, allowing the gel to flow. In the eye, this mechanism is partially attributable to the 20 blinking.eyelid. When the stress is removed (eyelid at rest ), the structure of the gel is partially re-established. Other factors which explain the duration of the formulations of the present invention are related to ionic interactions, and a release mechanism 25 which is explained by a dynamic equilibrium involving normal tear production and the displacement of basic active cations by cations present in tears. This ^hAni-~m is mentioned again, below.
Suitable polymers useful in the present invention 30 are carboxyl vinyl polymers. Preferred polymers of this class include the so called rArh~ s, available under the trade name Carbopol from the B . P . Goodrich Company; and ethylene maleic anhydride polymeric material, available under the trade name BMA from the 200D~4~8 Monsanto Company. The known and readily available polymers Carbopol 934 and 940 are specifically pref erred . The polymers are used in the aqueous gel compositions at a level up to about 8% by weight;
5 pourable liquid compositions comprise 0 . 05% to 2 . 0% by weight polymer.
Basic Active The preferred basic actives of the present invention are those disclosed above The most. preferred lO ba6ic actives are betaxolol and timolol. The basic active, in the gel and pourable liquid embodiments, is present at a level of from about 0.01 to 4.0 wt. %; the most preferred range is from 0 .10 to 1. 0 wt. % .
Ion Exchanqe Resin The cationic resin ~ t of the formulations of the present invention provides an additional means of sustained release of the basic active, and appears to be necessary for initial and prolonged comfort.
Such resins are characterized as either strongly acidic 20 such as those having sulfonic acid functionality, or weakly acidic cation exchangers such as those having carboxylic acid functionality. The resin must be incorporated as a finely divided powder, that is, 95%
of the resulting spheroidal particles must have a 25 diameter less than 20 . 0 microns . The release of the basic active held by the cation exchange resin and the anionic polymer is achieved when ions naturally present in the tear fluid, principally sodium and potassium, compete with the bound basic active for sites on the 30 polymer vehicle and the ion exchange resin. Thus released, the basic active is presented to the eye surface for transport to the receptor sites.
z~l3i4~8 Any pharmaceutical grade cationic ion exchange resin is suitable for the formulation, an they can be used either in the hy~lL~/y~n form or in the sodLum form.
Such resins are readily available, for example, from Rohm & Haas under the ~Amberlite~ ~rA~ ni and from Dow Chemical Co. under the ~Dowex~ trA~c-r\i .
The ion exchange resin ~ t is present in the f ormulations of the present invention at -a level of from 0.0596 to lO.O~i by weight. The average particle size diameter of the resin ranges from 1 to 20 microns.
The particle size of the resin is critical, both with respect to mode of action and comfort. Typically the average particle size of the commercially available f rom of the ion exchange material of choice is about 4 0 to 150 microns. Such particles are most conveniently reduced to a particle size range of about 1. 0 to 25 microns by ball milling, according to known techniques.
Other Inqredients Antimicrobial P~eservative:
Ophthalmic products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M, or other agents known to those skilled in the art. Typically such ~LeseLv~tives are employed at a level of from O . 001% to 1. O~i by weight .
TonicitY Aqents:
The tonicity, or osmolality, of the product can be ad justed to either hypotonicity, isotonicity or 21~0~4~:;8 hypertonicLty relative to normal tears by use of conventional materials known to the art. Such tonicity agents, however, are limited to nonionic compounds and typically, when employed, range from 0 . 096 to 1096 weight percent in the f inal product . Nonionic agents representatively include: mannitol, dextrose, glycerine and propyleneglycol; their presence in the final product form, however, is optional.
FormulatLon The composLtLons are formulated in three basic states: 1. ) gels; 2. )pourable liquids; and 3. ) anhydrous salts:
1. ) Gels The cationic exchange resin ~ nt is dispersed in water. The basic active ^ -t is then added with stirring. The polyanionic polymer component is then added.
The resulting product has a viscosity ranging from 1000 to 300,000 cpg rl~.pr.nr~n~
on the anionic polymer concentration. The resulting pH is 3 . 0 to 8 . 5, which may be adjusted, if n~c~R~ry, with HCl or ~aOH.
2. ) Pourable Liquids The cationic exchange resin _ ~ ~t is dispersed in 10 to 50 vol. percent of total water taken in formulation, and then basic active is dispersed and/or dissolved with stirring. The polyanionic polymer, as an aqueous dispersion, is added until the desired pH of the product is obtained. The pH of the product can be ad~usted to the desired value by varying basic active/polymer/resin ratio. If desired, ZC~0~68 final pH of product can be ad~usted with addltion of either NaOH or HCl. The pref erred pH range f or ophthalmic formulations if from 3.0 to 8.5. The final product is a dispersion, which may require high energy mixing to break any agglomeration to achieve llni f-~rmi ty. Other formulation ingredient6 are then added with mixing. The resulting product has a viscosity ranging from 1. 0 to 20, 000 cps depending on the anionic polymer concentration .
3. ) Anh~drous Salts The basic active, the ion exchange resin, and the polyanionic polymer are combined in water, and following mixing, are lyophilized to a powder. Fillers like mannitol and other materials may be added to facili~ate the freeze/drying processing according to techniques well known to those skilled in the art. The anhydrous salts produced in this manner can then be f ormulated or reconstituted to aqueous gels and liquids, or can be f ormulated and shaped as ocular insets . The lyo~hi 1 i 7-~cl powder can also be combined with a nonaqueous vehicle to ~orm an ophthalmic ointment.
Such anhydrous salt embodiments of the present invention can also be prepared by extracting the initial aqueous dispersion with an organic solvent such as ethanol, chloroform, benzene, or the like, and evaporating the organic solvent to produce 2~04~i8 ' 10 the deaired salt complex. The resulting product is substantially equivalent to the above-described lyorhi 1 i 7F.d product.
Utility The Ophthalmic formulations of the present invention are administered to the eyes as gel6, pourable liquid6 (eye drop6), and in the form of ointment6 and ocular in6erts; the latter cla6sifications are formulated form anhydrous salts.
All such compositions are formulated to control the release of the basic active upon administration to the eye and thereby provide a sustained release effect.
Typically such administration is necessary once or twice per day. The precise dosage regimen i6 lef t to the routine discretion of the clinlriJln.
The following examples illustrate, but do not limit the compositional or method of treatment aspects of the present invention.
E:xample 1 Pre~aration of BetaxglQl Free Base from Betaxolol HYdrochloride:
Betaxolol ~ydrochloride is disclosed in U. S .
Patent 4,252,984, and is commercially available.
Betaxolol Hydrochloride ( 0 . 88 moles ) is dissolved in water and the solution is chilled in an ice-bath.
To this solution is added a solution of sodium hydroxide ( 0 . 97 moles ) in water portionwise to make the mixture basic while it is stirred vigorously. At this point the pH of the mixture is approximately 9 . 6 . The resulting white solid is collected by f iltration and washed with a large volume of water.
200d~4~i8 After press/dryiny in the filter funnel, the semi-dry solid is resuspended in a large volume of water and stirred for 1-2 hours. The white solid i3 collected by f iltration and washed with a large volume of water to 5 afford salt-free Betaxolol free base, which is dried in vacuo .
Example 2 Product ComPOsitiOn A (wt%) B (wt%) C (wt%~
The pourable liquid ' ' i ts ( administered as drops to the eye ) of the present invention have a viscosity of from about 1 to 20,000 cps. The pH
25 requirements are the same as recited above for the gel f inal products, i . e ., pH 3 . 0-8 . 5 .
The thLrd pharmaceutical form of the present invention, the anhydrous salt form, is derived from a salt of the polycarboxylic acid polymer and the basic 30 active. (The presence of the cationic ion exchange resin also contributes to salt formation; thQ nature of the ion exchange resin, in all ~ Ls of the present invention, is defLned below. ) Such salts can 2~0~468 be formulated, or reconstituted, to aqueous gels and pourable dispersions, a6 described above, on addition of water; or can be formulated as ocular inserts according to known technology and shapes; or they can 5 be combined with an oleaginous vehicle to f orm an ophthalmic ointment. All such final ophthalmic pharmaceutical forms are fully described below.
The term ' plastic viscosity", above, is indicative of a materi~ l that does not perceptibly f low until a 10 certain force or stress value is exceeded; this force or stress is ref erred to as the yield value . While not wishing to be bound by any theory, it i8 believed that the increased duration of activity of the compositions of the present invention is related, in part, to the 15 yield value. The compositions of the present invention exhibit a unique response to shear stress. When the yield value is t-~ r~ d~ the gel structure is altered temporarily, allowing the gel to flow. In the eye, this mechanism is partially attributable to the 20 blinking.eyelid. When the stress is removed (eyelid at rest ), the structure of the gel is partially re-established. Other factors which explain the duration of the formulations of the present invention are related to ionic interactions, and a release mechanism 25 which is explained by a dynamic equilibrium involving normal tear production and the displacement of basic active cations by cations present in tears. This ^hAni-~m is mentioned again, below.
Suitable polymers useful in the present invention 30 are carboxyl vinyl polymers. Preferred polymers of this class include the so called rArh~ s, available under the trade name Carbopol from the B . P . Goodrich Company; and ethylene maleic anhydride polymeric material, available under the trade name BMA from the 200D~4~8 Monsanto Company. The known and readily available polymers Carbopol 934 and 940 are specifically pref erred . The polymers are used in the aqueous gel compositions at a level up to about 8% by weight;
5 pourable liquid compositions comprise 0 . 05% to 2 . 0% by weight polymer.
Basic Active The preferred basic actives of the present invention are those disclosed above The most. preferred lO ba6ic actives are betaxolol and timolol. The basic active, in the gel and pourable liquid embodiments, is present at a level of from about 0.01 to 4.0 wt. %; the most preferred range is from 0 .10 to 1. 0 wt. % .
Ion Exchanqe Resin The cationic resin ~ t of the formulations of the present invention provides an additional means of sustained release of the basic active, and appears to be necessary for initial and prolonged comfort.
Such resins are characterized as either strongly acidic 20 such as those having sulfonic acid functionality, or weakly acidic cation exchangers such as those having carboxylic acid functionality. The resin must be incorporated as a finely divided powder, that is, 95%
of the resulting spheroidal particles must have a 25 diameter less than 20 . 0 microns . The release of the basic active held by the cation exchange resin and the anionic polymer is achieved when ions naturally present in the tear fluid, principally sodium and potassium, compete with the bound basic active for sites on the 30 polymer vehicle and the ion exchange resin. Thus released, the basic active is presented to the eye surface for transport to the receptor sites.
z~l3i4~8 Any pharmaceutical grade cationic ion exchange resin is suitable for the formulation, an they can be used either in the hy~lL~/y~n form or in the sodLum form.
Such resins are readily available, for example, from Rohm & Haas under the ~Amberlite~ ~rA~ ni and from Dow Chemical Co. under the ~Dowex~ trA~c-r\i .
The ion exchange resin ~ t is present in the f ormulations of the present invention at -a level of from 0.0596 to lO.O~i by weight. The average particle size diameter of the resin ranges from 1 to 20 microns.
The particle size of the resin is critical, both with respect to mode of action and comfort. Typically the average particle size of the commercially available f rom of the ion exchange material of choice is about 4 0 to 150 microns. Such particles are most conveniently reduced to a particle size range of about 1. 0 to 25 microns by ball milling, according to known techniques.
Other Inqredients Antimicrobial P~eservative:
Ophthalmic products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M, or other agents known to those skilled in the art. Typically such ~LeseLv~tives are employed at a level of from O . 001% to 1. O~i by weight .
TonicitY Aqents:
The tonicity, or osmolality, of the product can be ad justed to either hypotonicity, isotonicity or 21~0~4~:;8 hypertonicLty relative to normal tears by use of conventional materials known to the art. Such tonicity agents, however, are limited to nonionic compounds and typically, when employed, range from 0 . 096 to 1096 weight percent in the f inal product . Nonionic agents representatively include: mannitol, dextrose, glycerine and propyleneglycol; their presence in the final product form, however, is optional.
FormulatLon The composLtLons are formulated in three basic states: 1. ) gels; 2. )pourable liquids; and 3. ) anhydrous salts:
1. ) Gels The cationic exchange resin ~ nt is dispersed in water. The basic active ^ -t is then added with stirring. The polyanionic polymer component is then added.
The resulting product has a viscosity ranging from 1000 to 300,000 cpg rl~.pr.nr~n~
on the anionic polymer concentration. The resulting pH is 3 . 0 to 8 . 5, which may be adjusted, if n~c~R~ry, with HCl or ~aOH.
2. ) Pourable Liquids The cationic exchange resin _ ~ ~t is dispersed in 10 to 50 vol. percent of total water taken in formulation, and then basic active is dispersed and/or dissolved with stirring. The polyanionic polymer, as an aqueous dispersion, is added until the desired pH of the product is obtained. The pH of the product can be ad~usted to the desired value by varying basic active/polymer/resin ratio. If desired, ZC~0~68 final pH of product can be ad~usted with addltion of either NaOH or HCl. The pref erred pH range f or ophthalmic formulations if from 3.0 to 8.5. The final product is a dispersion, which may require high energy mixing to break any agglomeration to achieve llni f-~rmi ty. Other formulation ingredient6 are then added with mixing. The resulting product has a viscosity ranging from 1. 0 to 20, 000 cps depending on the anionic polymer concentration .
3. ) Anh~drous Salts The basic active, the ion exchange resin, and the polyanionic polymer are combined in water, and following mixing, are lyophilized to a powder. Fillers like mannitol and other materials may be added to facili~ate the freeze/drying processing according to techniques well known to those skilled in the art. The anhydrous salts produced in this manner can then be f ormulated or reconstituted to aqueous gels and liquids, or can be f ormulated and shaped as ocular insets . The lyo~hi 1 i 7-~cl powder can also be combined with a nonaqueous vehicle to ~orm an ophthalmic ointment.
Such anhydrous salt embodiments of the present invention can also be prepared by extracting the initial aqueous dispersion with an organic solvent such as ethanol, chloroform, benzene, or the like, and evaporating the organic solvent to produce 2~04~i8 ' 10 the deaired salt complex. The resulting product is substantially equivalent to the above-described lyorhi 1 i 7F.d product.
Utility The Ophthalmic formulations of the present invention are administered to the eyes as gel6, pourable liquid6 (eye drop6), and in the form of ointment6 and ocular in6erts; the latter cla6sifications are formulated form anhydrous salts.
All such compositions are formulated to control the release of the basic active upon administration to the eye and thereby provide a sustained release effect.
Typically such administration is necessary once or twice per day. The precise dosage regimen i6 lef t to the routine discretion of the clinlriJln.
The following examples illustrate, but do not limit the compositional or method of treatment aspects of the present invention.
E:xample 1 Pre~aration of BetaxglQl Free Base from Betaxolol HYdrochloride:
Betaxolol ~ydrochloride is disclosed in U. S .
Patent 4,252,984, and is commercially available.
Betaxolol Hydrochloride ( 0 . 88 moles ) is dissolved in water and the solution is chilled in an ice-bath.
To this solution is added a solution of sodium hydroxide ( 0 . 97 moles ) in water portionwise to make the mixture basic while it is stirred vigorously. At this point the pH of the mixture is approximately 9 . 6 . The resulting white solid is collected by f iltration and washed with a large volume of water.
200d~4~i8 After press/dryiny in the filter funnel, the semi-dry solid is resuspended in a large volume of water and stirred for 1-2 hours. The white solid i3 collected by f iltration and washed with a large volume of water to 5 afford salt-free Betaxolol free base, which is dried in vacuo .
Example 2 Product ComPOsitiOn A (wt%) B (wt%) C (wt%~
10 Betaxolol O . 50 ` O . 25 1. 0 CARsOPOL-934 P (f~A ' ) 0.25 0.15 0.35 Sodium Poly ( Styrene-Divinyl senzene) Sulfonate 0.25 0.125 0.50 ~n 7;1 l kt-n ~ um Chloride O . 01 0 . 01 0 . 01 15Mannitol 5 . 0 5 . 0 5 . O
Water To Make 100%
Procedure Finely divided Amberlite IRP-69 resLn, a sodium poly(styrene-divinyl benzene) sulfonate, and the 20 betaxolol are mixed in 50% of the total water volume component to form a uniform dispersion. The Carbopol-934P is added slowly as an aqueous dispersion. The mixture is homogenized at high speed. The other ingredients are added as aqueous solutions. The final 25 volume is made on addition of water. The resultant products, A, B and C, are white unif~rm suspensions.
2C~0~468 ~ 12 .
ExamDle 3 Product ComPosition A (wt%~ B ~wt96) C (Wt96l Betaxolol Base 0 . 50 0 . 25 1. 0 5 Poly ( Styrene-Divinyl Benzene)Sulfonic acid 0.25 0.125 0.5 Carbopol-934P 0.20 0.1 0.35 BPn 7A 1 knn i um Chloride 0 . 01 0 . 01 0 . 01 Mannitol 5 . o 5 . 0 5 . 0 10Water To Make 10096 Procedure The solution6 A, B and C of Example 3 are prepared following the ~, ~,cedu. ~= of Example 2. The resulting products are white to off-white uniform suspensions 15 with pH between 5 . 5 to 6 . 5 .
Following the ~LoceduIe of Examples 2 ~nd 3, substantially equivalent results are obtained when the betaxolol t is replaced by an equivalent amount of timolol, or by any of the previously ident~fied beta 20 blockers and other basic actives, respectively.
The invention has been described herein with reference to certain preferred ~ Ls. However, as obvious variations thereon will become apparent to those skilled in the art, the invention is not to be 25 considered as limited thereto.
Water To Make 100%
Procedure Finely divided Amberlite IRP-69 resLn, a sodium poly(styrene-divinyl benzene) sulfonate, and the 20 betaxolol are mixed in 50% of the total water volume component to form a uniform dispersion. The Carbopol-934P is added slowly as an aqueous dispersion. The mixture is homogenized at high speed. The other ingredients are added as aqueous solutions. The final 25 volume is made on addition of water. The resultant products, A, B and C, are white unif~rm suspensions.
2C~0~468 ~ 12 .
ExamDle 3 Product ComPosition A (wt%~ B ~wt96) C (Wt96l Betaxolol Base 0 . 50 0 . 25 1. 0 5 Poly ( Styrene-Divinyl Benzene)Sulfonic acid 0.25 0.125 0.5 Carbopol-934P 0.20 0.1 0.35 BPn 7A 1 knn i um Chloride 0 . 01 0 . 01 0 . 01 Mannitol 5 . o 5 . 0 5 . 0 10Water To Make 10096 Procedure The solution6 A, B and C of Example 3 are prepared following the ~, ~,cedu. ~= of Example 2. The resulting products are white to off-white uniform suspensions 15 with pH between 5 . 5 to 6 . 5 .
Following the ~LoceduIe of Examples 2 ~nd 3, substantially equivalent results are obtained when the betaxolol t is replaced by an equivalent amount of timolol, or by any of the previously ident~fied beta 20 blockers and other basic actives, respectively.
The invention has been described herein with reference to certain preferred ~ Ls. However, as obvious variations thereon will become apparent to those skilled in the art, the invention is not to be 25 considered as limited thereto.
Claims (23)
1. An ophthalmic pharmaceutical composition for controlling and lowering intraocular pressure comprising a basic active, an anionic mucomimetic polymer, and a cation exchange resin.
2. The compositions according to claim 1 wherein the composition is an aqueous dispersion.
3. An ophthalmic pharmaceutical composition for controlling and lowering intraocular pressure as an aqueous dispersion comprising a basic active, an anionic mucuomimetic polymer, and a finely divided cation exchange resin.
4. The composition according to claim 3 wherein the basic active is betaxolol.
5. The composition according to claim 3 wherein the basic active is timolol.
6. The composition of claim 3 wherein the basic active is selected from pilocarpine, epinephrine, proepinephrine, norepinephrine, pronorepinephrine, clonidine, p-aminoclonidine, p-acetoamidoclonidine, or a beta-blocker selected from betaxolol, timolol, acebutolol, alprenolol, atenolol, bevantolol, bucomolol, bupranolol, butidrine, bunitolol, bunolol, butocrolol, butamine, carazolol, carteolol, exaprolol, indenolol, iprocrolol, labetolol, mepindolol, metipranolol, metaprolol, moprolol, nadolol, nifenalol, oxprenolol, pamatolol, paragolol, penbutolol, pindolol, practolol, procinolol, pronethalol, propranolol, sotalol, tazolol, tiprenolol, tolamolol, toliprolol, befunolol, esmalol, hepunolol, celiprolol, azotinolol, diacetalol, acebutolol, salbutanol, and isoxaprolol
7. A composition according to claim 1 which is a stained release ophthalmic pharmaceutical composition in the form of an aqueous gel, a pourable aqueous dispersion, or anhydrous salt, for controlling and lowering intraocular pressure comprising:
a therapeutically effective amount of a beta blocker of the formula:
R1-0-CH2-CH(OH)-CH2-NR2R3 wherein R1 is a substituted or unsubstituted cyclic or aliphatic moiety, and R2 and R3 are independently selected for H and substituted and unsubstituted alkyl;
an amount of an anionic mucomimetic polymer having carboxylic acid functional groups which comprise from 2 to 7 carbon atoms per function group and a molecular weight from 50,000 to 6 million such that the composition in the form of an aqueous gel or pourable aqueous dispersion has a viscosity of about 1 to 20,000 cps.; and a particulate cation exchange resin at a concentration of from about 0.05% to 10.0% by weight, the composition having a pH of from about 3.0 to 8.5.
a therapeutically effective amount of a beta blocker of the formula:
R1-0-CH2-CH(OH)-CH2-NR2R3 wherein R1 is a substituted or unsubstituted cyclic or aliphatic moiety, and R2 and R3 are independently selected for H and substituted and unsubstituted alkyl;
an amount of an anionic mucomimetic polymer having carboxylic acid functional groups which comprise from 2 to 7 carbon atoms per function group and a molecular weight from 50,000 to 6 million such that the composition in the form of an aqueous gel or pourable aqueous dispersion has a viscosity of about 1 to 20,000 cps.; and a particulate cation exchange resin at a concentration of from about 0.05% to 10.0% by weight, the composition having a pH of from about 3.0 to 8.5.
8. The compositions of claim 7 wherein the particulate cation exchange resin is in the form of a finely divided powder, said powder consisting of spherical particles.
9. The composition of claim 8 wherein the cation exchange resin is sodium poly(styrene divinylbenzene) sulfonic acid and the beta blocker is betaxolol.
10. A composition according to claim 7 wherein the beta blocker is present at a concentration of about 0.25wt.%, the anionic mucomimetic polymer is present at a concentration of about 0.20wt% and the cation exchange resin is present at a concentration of about 0.25wt%.
11. A sustained release ophthalmic pharmaceutical composition in the form of an aqueous gel, a pourable aqueous dispersion, or anhydrous salt, for controlling and lowering intraocular pressure comprising:
a therapeutically effective amount of a beta blocker;
an amount of an anionic mucomimetic polymer having carboxylic acid functional groups which comprise from 2 to 7 carbon atoms per functional group and a molecular weight of from 50,000 to 6 million such that the composition in the form of an aqueous gel or pourable aqueous dispersion has a viscosity of about 1 to about 20,000cps, and sodium poly(-styrenedivinylbenzene) sulfonic acid at a concentration of from about 0.05% to 10.0% by weight, the composition having a pH of from about 3.0 to 8.5.
a therapeutically effective amount of a beta blocker;
an amount of an anionic mucomimetic polymer having carboxylic acid functional groups which comprise from 2 to 7 carbon atoms per functional group and a molecular weight of from 50,000 to 6 million such that the composition in the form of an aqueous gel or pourable aqueous dispersion has a viscosity of about 1 to about 20,000cps, and sodium poly(-styrenedivinylbenzene) sulfonic acid at a concentration of from about 0.05% to 10.0% by weight, the composition having a pH of from about 3.0 to 8.5.
12. The composition according to claim 11 wherein the composition is an aqueous dispersion.
13. A composition acording to claim 11 wherein the beta blocker is betaxolol and is present at a concentration of from about 0.01 to 4.0 wt %.
14. A composition according to claim 11 wherein the anionic mucomimetic polymer comprises carbomer.
15. A composition according to claim 11 wherein the beta blocker is betaxolol and is present at a concentration of about 0.25 wt %, the anionic mucomimetic polymer is carbomer present at a concentration of about 0.20 wt %, and the sulfonic acid is present at a concentration of about 0.25 wt %.
16. The composition of claim 11 wherein the particulate cation exchange resin is in the form of a finely divided powder, said powder consisting of spheroidal particles.
17. The composition according to claim 11, wherein the anionic mucomimetic polymer is a carboxy vinyl polymer.
18. The composition according to claim 17, wherein the carboxy vinyl resin is Carbopol 934.
19. The composition according to claim 17, wherein the carboxy vinyl resin is Carbopol 940.
20. The composition according to claim 11, further comprising an antimicrobial preservative.
21. The composition according to claim 20, wherein the antimicrobial preservative is benzalkonium chloride.
22. The composition according to claim 11, further comprising a tonicity agent.
23. The composition according to claim 22, wherein the tonicity agent is mannitol.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/154,514 US4911920A (en) | 1986-07-30 | 1988-02-05 | Sustained release, comfort formulation for glaucoma therapy |
AU45753/89A AU621692B2 (en) | 1986-07-30 | 1989-11-30 | Sustained release, comfort formulation for glaucoma therapy |
CA002004468A CA2004468C (en) | 1988-02-05 | 1989-12-01 | Sustained release, comfort formulation for glaucoma therapy |
DE68913979T DE68913979T2 (en) | 1988-02-05 | 1989-12-01 | Medicinal preparations containing delayed release of active substances containing cation exchange resins and carboxyl-containing synthetic resins. |
IL9252789A IL92527A (en) | 1988-02-05 | 1989-12-01 | Opthalmic pharmaceutical composition for glaucoma therapy |
EP89312590A EP0429732B1 (en) | 1986-07-30 | 1989-12-01 | Sustained-release compositions containing cation exchange resins and polycarboxylic polymers |
JP1321616A JPH0725698B2 (en) | 1984-10-31 | 1989-12-13 | Formulation for the treatment of glaucoma with sustained release and comfortable application |
US08/334,512 US5554367A (en) | 1984-10-31 | 1994-11-04 | Compositions for treatment of glaucoma |
US08/396,284 US5635172A (en) | 1984-10-31 | 1995-02-27 | Sustained release comfort formulation for glaucoma therapy |
HK135695A HK135695A (en) | 1986-07-30 | 1995-08-24 | Sustained-release compositions containing cation exchange resins and polycarboxylic polymers |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/154,514 US4911920A (en) | 1986-07-30 | 1988-02-05 | Sustained release, comfort formulation for glaucoma therapy |
CA002004468A CA2004468C (en) | 1988-02-05 | 1989-12-01 | Sustained release, comfort formulation for glaucoma therapy |
IL9252789A IL92527A (en) | 1988-02-05 | 1989-12-01 | Opthalmic pharmaceutical composition for glaucoma therapy |
JP1321616A JPH0725698B2 (en) | 1984-10-31 | 1989-12-13 | Formulation for the treatment of glaucoma with sustained release and comfortable application |
HK135695A HK135695A (en) | 1986-07-30 | 1995-08-24 | Sustained-release compositions containing cation exchange resins and polycarboxylic polymers |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2004468A1 CA2004468A1 (en) | 1991-06-01 |
CA2004468C true CA2004468C (en) | 1996-10-01 |
Family
ID=27508398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002004468A Expired - Lifetime CA2004468C (en) | 1984-10-31 | 1989-12-01 | Sustained release, comfort formulation for glaucoma therapy |
Country Status (7)
Country | Link |
---|---|
US (2) | US4911920A (en) |
EP (1) | EP0429732B1 (en) |
AU (1) | AU621692B2 (en) |
CA (1) | CA2004468C (en) |
DE (1) | DE68913979T2 (en) |
HK (1) | HK135695A (en) |
IL (1) | IL92527A (en) |
Families Citing this family (293)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554367A (en) * | 1984-10-31 | 1996-09-10 | Alcon Laboratories, Inc. | Compositions for treatment of glaucoma |
US5093126A (en) * | 1987-09-26 | 1992-03-03 | Alcon Laboratories, Inc. | Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer |
US5188826A (en) * | 1988-02-08 | 1993-02-23 | Insite Vision Incorporated | Topical ophthalmic suspensions |
US5192535A (en) * | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
US5461081A (en) * | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
US5521222A (en) * | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
US5660851A (en) * | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
US5496471A (en) * | 1990-01-08 | 1996-03-05 | Ciba-Geigy Corporation | Apparatus for removing components from solutions |
US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
US5833665A (en) * | 1990-06-14 | 1998-11-10 | Integra Lifesciences I, Ltd. | Polyurethane-biopolymer composite |
US5252318A (en) * | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
US5275820A (en) * | 1990-12-27 | 1994-01-04 | Allergan, Inc. | Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles |
US5212162A (en) * | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
CA2064160C (en) * | 1991-03-27 | 1998-08-11 | Paul J. T. Missel | Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US5182102A (en) * | 1991-07-12 | 1993-01-26 | Alcon Laboratories, Inc. | Anti-glaucoma compositions |
EP0606393A1 (en) * | 1991-10-11 | 1994-07-20 | Alcon Laboratories, Inc. | Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use |
US5320839A (en) * | 1991-10-11 | 1994-06-14 | Alcon Laboratories, Inc. | Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use |
JP2873530B2 (en) * | 1991-12-13 | 1999-03-24 | 参天製薬株式会社 | Carboxyvinyl polymer-containing ophthalmic base showing Newtonian viscosity |
US5932572A (en) * | 1992-02-21 | 1999-08-03 | Alcon Laboratories, Inc. | Topical anti-glaucoma compositions |
ATE169499T1 (en) * | 1992-02-21 | 1998-08-15 | Alcon Lab Inc | TOPICAL ANTIGLAUCOMA COMPOSITIONS CONTAINING CARBON HYDRASE INHIBITORS AND BETA BLOCKERS |
US5296228A (en) * | 1992-03-13 | 1994-03-22 | Allergan, Inc. | Compositions for controlled delivery of pharmaceutical compounds |
TW205503B (en) * | 1992-04-24 | 1993-05-11 | Ciba Geigy Ag | Apparatus for removing components from solutions |
WO1993023082A1 (en) * | 1992-05-13 | 1993-11-25 | Alcon Laboratories, Inc. | Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents |
US5520920A (en) * | 1992-08-28 | 1996-05-28 | Alcon Laboratories, Inc. | Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions |
AU666957B2 (en) | 1992-08-28 | 1996-02-29 | Alcon Laboratories, Inc. | Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions |
JP3002258B2 (en) * | 1992-10-13 | 2000-01-24 | アルコン ラボラトリーズ, インコーポレイテッド | Combination of prostaglandin and clonidine derivatives for the treatment of glaucoma |
US5340572A (en) * | 1993-02-08 | 1994-08-23 | Insite Vision Incorporated | Alkaline ophthalmic suspensions |
WO1995005161A1 (en) * | 1993-08-13 | 1995-02-23 | Vitaphore Corporation | Hydrogel-based microsphere drug delivery systems |
WO1995030420A1 (en) * | 1994-05-06 | 1995-11-16 | Alcon Laboratories, Inc. | Use of vitamin e tocopheryl derivatives in ophthalmic compositions |
US5662919A (en) * | 1994-11-21 | 1997-09-02 | Alcon Laboratories, Inc. | Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds |
US5612027A (en) * | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
US6172054B1 (en) | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
WO1997018812A1 (en) * | 1995-11-17 | 1997-05-29 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
US6441047B2 (en) | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
EP0868186B1 (en) | 1995-12-21 | 2005-03-02 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
US6159458A (en) * | 1997-11-04 | 2000-12-12 | Insite Vision | Sustained release ophthalmic compositions containing water soluble medicaments |
AU761785B2 (en) * | 1998-09-25 | 2003-06-12 | Alcon Laboratories, Inc. | Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
US6146622A (en) * | 1998-10-27 | 2000-11-14 | Alcon Laboratories, Inc. | Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions |
US6444710B1 (en) | 1998-10-27 | 2002-09-03 | Alcon Manufacturing, Ltd. | Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions |
CA2340225A1 (en) | 1998-10-27 | 2000-05-04 | Wesley Wehsin Han | Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap |
AU758450B2 (en) | 1998-10-27 | 2003-03-20 | Alcon Laboratories, Inc. | Preservative system for topically administrable pharmaceutical compositions |
US6258350B1 (en) | 1999-01-20 | 2001-07-10 | Alcon Manufacturing, Ltd. | Sustained release ophthalmic formulation |
CA2359116C (en) | 1999-01-25 | 2009-03-17 | National Jewish Medical And Research Center | Substituted porphyrins |
WO2000069411A1 (en) * | 1999-05-12 | 2000-11-23 | Alcon Laboratories, Inc. | Use of polymeric adsorbents in pharmaceutical dosage forms |
US6730691B1 (en) | 2000-02-10 | 2004-05-04 | Miles A. Galin | Uses of alpha adrenergic blocking agents |
DE10115282B4 (en) * | 2000-03-29 | 2006-03-02 | Hitachi, Ltd. | Inlet air control device and internal combustion engine in which it is mounted |
PE20020578A1 (en) | 2000-10-10 | 2002-08-14 | Upjohn Co | A TOPICAL ANTIBIOTIC COMPOSITION FOR THE TREATMENT OF EYE INFECTIONS |
US20040121947A1 (en) * | 2000-12-28 | 2004-06-24 | Oklahoma Medical Research Foundation | Compounds which inhibit beta-secretase activity and methods of use thereof |
US20020176842A1 (en) * | 2001-04-09 | 2002-11-28 | Lyn Hughes | Extended release of active ingredients |
AU2002312194B8 (en) * | 2001-06-01 | 2008-05-15 | Aeolus Sciences, Inc. | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
US6743439B1 (en) | 2001-06-27 | 2004-06-01 | Alcon, Inc. | Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride |
US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
US20040067992A1 (en) * | 2001-08-10 | 2004-04-08 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
US20030220376A1 (en) * | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
US20030099711A1 (en) * | 2001-08-29 | 2003-05-29 | David Meadows | Sustained release preparations |
AU2002359301B2 (en) * | 2001-10-23 | 2008-07-03 | Comentis, Inc. | Beta-secretase inhibitors and methods of use |
US20060234944A1 (en) * | 2001-10-23 | 2006-10-19 | Oklahoma Medical Reseach Foundation | Beta-secretase inhibitors and methods of use |
US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
IL165910A0 (en) * | 2002-07-03 | 2006-01-15 | Pericor Science Inc | Compositions of hyaluronic acid and methods of use |
US20050031652A1 (en) * | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
US20050147584A1 (en) * | 2004-01-05 | 2005-07-07 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
US20050277698A1 (en) * | 2004-01-05 | 2005-12-15 | Hughes Patrick M | Memantine delivery to the back of the eye |
US20050265955A1 (en) * | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
JP2008513495A (en) * | 2004-09-17 | 2008-05-01 | コメンティス,インコーポレーテッド | Bicyclic compounds that inhibit beta-secretase activity and methods of use thereof |
JP2008513497A (en) * | 2004-09-17 | 2008-05-01 | コメンティス,インコーポレーテッド | Amino-containing compounds that inhibit memapsin 2β secretase activity and methods of use thereof |
WO2006062731A1 (en) * | 2004-11-19 | 2006-06-15 | University Of North Texas Health Science Center At Fort Worth | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye |
JP2008520744A (en) * | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Anti-inflammatory pyrazolopyrimidine |
KR20080015079A (en) * | 2005-04-08 | 2008-02-18 | 코멘티스, 인코포레이티드 | Compounds which inhibit beta-secretase activity and methods of use thereof |
US20070077302A1 (en) * | 2005-09-30 | 2007-04-05 | Azaam Alli | Methods for stabilizing ophthalmic compositions |
CA2630668C (en) * | 2005-11-22 | 2016-07-12 | Mcgill University | Intraocular pressure-regulated early genes and uses thereof |
JP5642963B2 (en) | 2006-06-30 | 2014-12-17 | スネシス ファーマシューティカルズ,インコーポレイティド | Pyridinonyl PDK1 inhibitor |
US8158667B2 (en) * | 2006-08-21 | 2012-04-17 | Kador Peter F | Topical treatment of cataracts in dogs |
AU2011253937B2 (en) * | 2006-12-05 | 2012-09-27 | The Royal Institution For The Advancement Of Learning/ Mcgill University | Methods of use of TRK receptor modulators |
AU2007327990A1 (en) * | 2006-12-05 | 2008-06-12 | The Royal Institution For The Advancement Of Learning/ Mcgill University | Methods of use of TRK receptor modulators |
JP5658031B2 (en) | 2007-06-22 | 2015-01-21 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Formation of stable submicron peptide or protein particles by thin film freezing |
WO2009015369A2 (en) * | 2007-07-26 | 2009-01-29 | Comentis, Inc. | Compounds which inhibit beta-secretase activity and methods of use thereof |
WO2009042694A1 (en) * | 2007-09-24 | 2009-04-02 | Comentis, Inc. | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
EP2300003B1 (en) | 2008-05-23 | 2014-03-05 | National Jewish Health | Compounds for use in treating injury associated with exposure to an alkylating species |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
WO2010011684A2 (en) * | 2008-07-21 | 2010-01-28 | The Regents Of The University Of California | Prodrug and fluoregenic compositions and methods for using the same |
AU2009290617B2 (en) | 2008-09-15 | 2015-05-14 | Fundacion Ciencia Para La Vida | Methods and compositions for modulating Ire1, Src, and Abl activity |
RU2482851C2 (en) * | 2009-02-20 | 2013-05-27 | Микро Лабс Лимитед | Storage of stable preparation of prostaglandin |
CN102753177A (en) | 2009-08-17 | 2012-10-24 | 纪念斯隆-凯特琳癌症中心 | Heat shock protein binding compounds, compositions, and methods for making and using same |
TWI557127B (en) | 2009-09-04 | 2016-11-11 | 百健Ma公司 | Bruton's tyrosine kinase inhibitors |
WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
CA2776690C (en) | 2009-10-06 | 2020-05-12 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as pdk1 inhibitors |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
CA2778825C (en) | 2009-10-26 | 2018-05-22 | Sephoris Pharmaceuticals, Llc | Treatment of sunburn using analgesics and antihistamines |
CN102711765A (en) | 2009-11-16 | 2012-10-03 | 加利福尼亚大学董事会 | Kinase inhibitors |
RU2517174C2 (en) | 2009-12-10 | 2014-05-27 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа | Amyloid-binding agents |
EP2560966B1 (en) | 2010-03-30 | 2021-01-06 | Verseon International Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
WO2012058645A1 (en) | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
JP5885271B2 (en) | 2011-02-14 | 2016-03-15 | アラーガン、インコーポレイテッドAllergan,Incorporated | Compositions and methods of ester derivatives of bimatoprost |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
BR112013029508B1 (en) | 2011-05-17 | 2022-05-03 | Principia Biopharma, Inc. | Compound, pharmaceutical composition, and use of said compound |
CA2836410C (en) | 2011-05-17 | 2019-08-20 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2012162547A2 (en) | 2011-05-25 | 2012-11-29 | Amylin Pharmaceuticals, Inc. | Long duration dual hormone conjugates |
AU2012279154A1 (en) | 2011-07-01 | 2014-02-20 | The Regents Of The University Of California | Herpes virus vaccine and methods of use |
AU2012341028C1 (en) | 2011-09-02 | 2017-10-19 | Mount Sinai School Of Medicine | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9073851B2 (en) | 2011-10-28 | 2015-07-07 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer |
CN104379563B (en) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | Composition and method for treating cancer |
US9353087B2 (en) | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
AR091273A1 (en) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | PYRIMIDINYL TIROSINE KINASE INHIBITORS |
WO2013188452A1 (en) | 2012-06-11 | 2013-12-19 | The Regents Of The University Of California | Compounds and methods of treating cancer |
ES2711425T3 (en) | 2012-08-27 | 2019-05-03 | Allergan Inc | Thickening of the reduced central cornea by the use of hydrophilic ester prodrugs of beta-chlorocyclopentanes |
US9090595B2 (en) | 2012-08-27 | 2015-07-28 | Allergan, Inc. | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes |
KR102203990B1 (en) | 2012-09-10 | 2021-01-18 | 프린시피아 바이오파마, 인코퍼레이티드 | Pyrazolopyrimidine compounds as kinase inhibitors |
SG11201502331RA (en) | 2012-09-26 | 2015-04-29 | Univ California | Modulation of ire1 |
EP2909214B1 (en) | 2012-10-22 | 2020-07-22 | City of Hope | Etp derivatives |
US9364462B2 (en) | 2012-10-30 | 2016-06-14 | The Regents Of The University Of California | Alpha-1-adrenergic receptor agonist therapy |
NZ710444A (en) | 2013-02-11 | 2020-08-28 | Univ California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
WO2014143591A1 (en) | 2013-03-12 | 2014-09-18 | Allergan, Inc. | Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors |
US9938263B2 (en) | 2013-03-12 | 2018-04-10 | The General Hospital Corporation | Gamma-secretase modulators |
US9321745B2 (en) | 2013-03-12 | 2016-04-26 | Allergan, Inc. | Inhibition of neovascularization by inhibition of prostanoid IP receptors |
WO2014153009A2 (en) | 2013-03-14 | 2014-09-25 | The Regents Of The University Of California, A California Corporation | Thiosaccharide mucolytic agents |
CN105283456B (en) | 2013-03-14 | 2018-12-18 | 希望之城 | The bromo- indigo red of 5- |
WO2014165307A2 (en) | 2013-03-14 | 2014-10-09 | The Regents Of The University Of California | Modulation of k2p channels |
AU2014238478B2 (en) | 2013-03-15 | 2018-07-19 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
CN107056838A (en) | 2013-03-15 | 2017-08-18 | 加利福尼亚大学董事会 | Acyclic nucleoside phosphonate diester |
WO2014146111A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Analgesic compounds and methods of use |
EP2968361A1 (en) | 2013-03-15 | 2016-01-20 | Allergan, Inc. | Bimatoprost for enhancement of leptin production |
JP6806562B2 (en) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Regulator of the eIF2α pathway |
UY35464A (en) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | KRAS G12C COVALENT INHIBITORS. |
CN110101700A (en) | 2013-03-15 | 2019-08-09 | 维颂公司 | The pharmaceutical applications of polysubstituted aromatic compounds as serpin |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
CA2949048A1 (en) | 2013-05-22 | 2014-11-27 | The Regents Of The University Of California | Aurora kinase inhibitors |
US9795691B2 (en) | 2013-06-24 | 2017-10-24 | City Of Hope | Chemically-linked nanoparticles |
CA2917527C (en) | 2013-07-15 | 2022-06-14 | Board Of Regents, The University Of Texas System | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain |
LT3035926T (en) | 2013-08-19 | 2020-11-25 | The Regents Of The University Of California | Compounds and methods for treating an epileptic disorder |
CN105979941A (en) | 2013-08-20 | 2016-09-28 | 希望之城 | Photo composition and position guidance in an imaging device |
WO2015031799A1 (en) | 2013-08-30 | 2015-03-05 | The Regents Of The University Of California, A California Corporation | Scintillator nanocrystal-containing compositions and methods for their use |
TWI659021B (en) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Inhibitors of kras g12c |
CA2932608C (en) | 2013-12-11 | 2023-02-14 | Biogen Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
WO2015089327A1 (en) | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
CA2934850C (en) | 2013-12-23 | 2022-12-06 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
WO2015116856A2 (en) | 2014-01-29 | 2015-08-06 | City Of Hope | Farnesoid x receptor antagonists |
US10167286B2 (en) | 2014-02-11 | 2019-01-01 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
CA2937752C (en) | 2014-02-14 | 2023-02-07 | The Regents Of The University Of California | Cyclic peroxides as prodrugs for selective delivery of agents |
TR201902864T4 (en) | 2014-02-20 | 2019-03-21 | Allergan Inc | Reduced central corneal thickening by the use of hydrophilic ester prodrugs of beta-chlorocyclopentanes. |
PT3107544T (en) | 2014-02-21 | 2021-01-05 | Principia Biopharma Inc | Salts and solid form of a btk inhibitor |
US20150259288A1 (en) | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
EP3128842B1 (en) | 2014-03-26 | 2023-07-26 | City of Hope | Treatment of brca1-defective cancer or resistant cancers |
EP3988540A1 (en) | 2014-04-07 | 2022-04-27 | The Regents of the University of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
ES2774975T3 (en) | 2014-05-13 | 2020-07-23 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods of making and using it |
WO2015183794A1 (en) | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
WO2016004383A1 (en) | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
US11072681B2 (en) | 2014-07-28 | 2021-07-27 | The Regents Of The University Of California | Compositions and methods of making polymerizing nucleic acids |
EP3954362A1 (en) | 2014-07-28 | 2022-02-16 | Sun Pharma Advanced Research Company Ltd | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug |
WO2016023036A1 (en) | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | High density peptide polymers |
CN113620978A (en) | 2014-09-11 | 2021-11-09 | 加利福尼亚大学董事会 | mTORC1 inhibitors |
HRP20220651T1 (en) | 2014-09-15 | 2022-08-19 | The Regents Of The University Of California | Nucleotide analogs |
CN106687445A (en) | 2014-09-17 | 2017-05-17 | 维颂公司 | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
WO2016049524A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
WO2016054596A1 (en) | 2014-10-02 | 2016-04-07 | Allergan, Inc. | Ester prodrugs of gamma-lactams and their use |
SG10201903210WA (en) | 2014-12-15 | 2019-05-30 | Univ Johns Hopkins | Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders |
EP3233103B1 (en) | 2014-12-18 | 2020-10-14 | Principia Biopharma Inc. | Treatment of pemphigus |
EP3733696A1 (en) | 2015-01-13 | 2020-11-04 | City of Hope | Ctla4-binding protein peptide-linker masks |
WO2016115500A1 (en) | 2015-01-16 | 2016-07-21 | City Of Hope | Cell penetrating antibodies |
US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
EA201791882A1 (en) | 2015-02-25 | 2018-02-28 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа | 5HT AGONISTS FOR THE TREATMENT OF VIOLATIONS |
BR112017018092A2 (en) | 2015-02-27 | 2018-04-10 | Verseon Corp | compound, pharmaceutical composition, and method for treating and / or preventing a disease or disorder. |
EA039121B1 (en) | 2015-02-27 | 2021-12-07 | Куртана Фармасьютикалс, Инк. | INHIBITION OF Olig2 ACTIVITY |
WO2016138533A2 (en) | 2015-02-27 | 2016-09-01 | The Regents Of The University Of California | Small molecules that enable cartilage rejuvanation |
EP3277712A4 (en) | 2015-03-30 | 2018-09-26 | City of Hope | Mechanically interlocking complexes |
KR20180005178A (en) | 2015-04-10 | 2018-01-15 | 아락세스 파마 엘엘씨 | Substituted quinazoline compounds and methods for their use |
WO2016168540A1 (en) | 2015-04-15 | 2016-10-20 | Araxes Pharma Llc | Fused-tricyclic inhibitors of kras and methods of use thereof |
WO2016166604A1 (en) | 2015-04-17 | 2016-10-20 | Ludwig Institute For Cancer Research Ltd | Plk4 inhibitors |
JP6704000B2 (en) | 2015-04-24 | 2020-06-03 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Modulator of ROR1-ROR2 binding |
US9574014B2 (en) | 2015-05-15 | 2017-02-21 | City Of Hope | Chimeric antigen receptor compositions |
WO2016185000A1 (en) * | 2015-05-21 | 2016-11-24 | Ophtalmis Monaco | Ophthalmic composition comprising lipoic acid and a mucomimetic polymer |
US10787664B2 (en) | 2015-05-26 | 2020-09-29 | City Of Hope | Compounds of chemically modified oligonucleotides and methods of use thereof |
US20180282310A1 (en) | 2015-06-10 | 2018-10-04 | Biogen Ma Inc. | Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase |
WO2016201169A1 (en) | 2015-06-10 | 2016-12-15 | City Of Hope | Compositions of and methods of treatment with zwitterionic polysaccharide |
WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
JP7073109B2 (en) | 2015-07-02 | 2022-05-23 | シティ・オブ・ホープ | Compounds and compositions containing phosphorothioated oligodeoxynucleotides, and their usage |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
JP7104462B2 (en) | 2015-08-06 | 2022-07-21 | シティ・オブ・ホープ | Cell-permeable protein-antibody conjugate and usage |
US11136301B2 (en) | 2015-08-31 | 2021-10-05 | The Regents of the University of California, A California Corporation et al. | Broad spectrum antiviral compounds and uses thereof |
WO2017040982A1 (en) | 2015-09-02 | 2017-03-09 | The Regents Of The University Of California | Her3 ligands and uses thereof |
CN108349900A (en) | 2015-09-04 | 2018-07-31 | 希望之城 | Androgen receptor antagonists |
CN108430978B (en) | 2015-09-25 | 2022-11-22 | 路德维格癌症研究所有限责任公司 | 3-hydroxy-quinazoline-2, 4-dione derivatives and their use as nuclease modulators |
EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10801026B2 (en) | 2015-10-15 | 2020-10-13 | City Of Hope | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
EP3364977A4 (en) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | Method for screening inhibitors of ras |
AU2016342352B2 (en) | 2015-10-23 | 2022-06-02 | Sunesis Pharmaceuticals, Inc. | Heterocyclic PDK1 inhibitors for use to treat cancer |
JP7034078B2 (en) | 2015-10-23 | 2022-03-11 | イーアールエックス ファーマシューティカルズ インコーポレイテッド | Celastrol analogue |
US11058700B2 (en) | 2015-10-28 | 2021-07-13 | City Of Hope | Macrocyclic lactones and uses thereof as modulators of purinergic receptors |
JP2018533596A (en) | 2015-11-12 | 2018-11-15 | グレイバグ ビジョン インコーポレイテッド | Aggregated microparticles for medical therapy |
EP3377481A1 (en) | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
CN112274649A (en) | 2015-12-10 | 2021-01-29 | 希望之城 | Cell penetrating cyanine conjugated antibodies |
KR20180101416A (en) | 2015-12-24 | 2018-09-12 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | CFTR modulators and methods for their use |
CA3009510A1 (en) | 2015-12-24 | 2017-06-29 | The Regents Of The University Of California | Phenylamino-1,3,5- triazine derivatives and use thereof as cftr regulators |
CN108697690B (en) | 2016-01-05 | 2022-01-14 | 加利福尼亚大学董事会 | Benzothiazole amphiphiles |
US10519442B2 (en) | 2016-02-11 | 2019-12-31 | City Of Hope | Twist signaling inhibitor compositions and methods of using the same |
EP3430017B1 (en) | 2016-03-17 | 2023-01-25 | The Regents of The University of California | Compositions and methods for treating parasitic diseases |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
ES2886935T3 (en) | 2016-04-25 | 2021-12-21 | Forma Therapeutics Inc | FASN inhibitors for use in the treatment of nonalcoholic steatohepatitis |
AU2017257151A1 (en) | 2016-04-29 | 2018-11-15 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
TW202304851A (en) | 2016-05-05 | 2023-02-01 | 美商嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
TW201808914A (en) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
CN109503637B (en) | 2016-05-12 | 2021-03-16 | 安纳考尔医药公司 | Compounds for the treatment of parasitic diseases |
EP3463342B1 (en) | 2016-05-26 | 2023-09-06 | The Regents of The University of California | Estrogen receptor modulator combinations |
CN115054586A (en) | 2016-06-29 | 2022-09-16 | 普林斯匹亚生物制药公司 | Modified release formulations |
WO2018013609A2 (en) | 2016-07-11 | 2018-01-18 | The Regents The University Of California | Synthetic melanin nanoparticles uses thereof |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
KR20190035769A (en) | 2016-07-21 | 2019-04-03 | 바이오젠 엠에이 인코포레이티드 | The form and composition of succinate of Brutonyl tyrosine kinase inhibitor |
PL3490565T3 (en) | 2016-07-29 | 2022-09-26 | Rapt Therapeutics, Inc. | Azetidine derivatives as chemokine receptor modulators and uses thereof |
US11254667B2 (en) | 2016-08-17 | 2022-02-22 | Children's Hospital Medical Center | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors |
US11542261B2 (en) | 2016-08-17 | 2023-01-03 | Children's Hospital Medical Center | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors |
WO2018039612A1 (en) | 2016-08-26 | 2018-03-01 | The Regents Of The University Of California | Compositions and methods for promoting hair growth with mpc1 inhibitors |
EP3512535A4 (en) | 2016-09-13 | 2020-05-06 | The Jackson Laboratory | Targeted enhanced dna demethylation |
US10822353B2 (en) | 2016-09-15 | 2020-11-03 | City Of Hope | Dithio ETP derivatives |
US10849955B2 (en) | 2016-09-28 | 2020-12-01 | City Of Hope | Methods of treating pancreatic cancer using GPCR antagonists |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
CN110312711A (en) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | Heterocyclic compound and its application method as RAS inhibitor |
US10646540B2 (en) | 2016-11-18 | 2020-05-12 | City Of Hope | Peptide inhibitors of twist |
MX2019007030A (en) | 2016-12-15 | 2020-01-15 | Univ California | Compositions and methods for treating cancer. |
US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
JP7327802B2 (en) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | Fused hetero-heterobicyclic compounds and methods of use thereof |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
WO2018175922A1 (en) | 2017-03-23 | 2018-09-27 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
JP2020519585A (en) | 2017-05-10 | 2020-07-02 | グレイバグ ビジョン インコーポレイテッド | Extended release microparticles and suspensions thereof for medical therapy |
JP2020521741A (en) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | Compounds for the treatment of cancer and methods of their use |
SG10202113146UA (en) | 2017-05-25 | 2021-12-30 | Araxes Pharma Llc | Covalent inhibitors of kras |
CN110831933A (en) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | Quinazoline derivatives as modulators of mutated KRAS, HRAS or NRAS |
KR20200019228A (en) | 2017-06-21 | 2020-02-21 | 미토키닌, 인크. | Compositions for the Treatment of Neurodegenerative and Mitochondrial Diseases and Methods of Using the Same |
US11554178B2 (en) | 2017-06-30 | 2023-01-17 | City Of Hope | Compositions and methods of modulating macrophage activity |
US11389460B2 (en) | 2017-09-15 | 2022-07-19 | City Of Hope | Methods and compositions for treating endometrial cancer |
WO2019067498A2 (en) | 2017-09-29 | 2019-04-04 | Genentech, Inc. | Peptide antibiotic complexes and methods of use thereof |
US20200354452A1 (en) | 2017-09-29 | 2020-11-12 | City Of Hope | Cars and bispecific antibodies for treatment of mantle cell lymphoma |
WO2019070917A1 (en) | 2017-10-03 | 2019-04-11 | The Schepens Eye Research Institute, Inc. | Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same |
CA3078942A1 (en) | 2017-10-10 | 2019-04-18 | Syros Pharmaceuticals, Inc. | Pyrrolotriazine compounds and methods of inhibiting tam kinases |
US11618780B2 (en) | 2017-10-20 | 2023-04-04 | City Of Hope | Composition and method for activating latent human immunodeficiency virus (HIV) |
BR112020008817B8 (en) | 2017-11-02 | 2023-10-03 | Abbvie Inc | Integrated stress pathway modulating compounds |
MX2020004537A (en) | 2017-11-02 | 2020-10-05 | Calico Life Sciences Llc | Modulators of the integrated stress pathway. |
MX2020004557A (en) | 2017-11-02 | 2020-10-05 | Calico Life Sciences Llc | Modulators of the integrated stress pathway. |
UY37956A (en) | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
UY37958A (en) | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
BR112020008825A2 (en) | 2017-11-02 | 2020-10-20 | Calico Life Sciences Llc | modulators of the integrated stress pathway |
US20230192712A1 (en) | 2017-11-02 | 2023-06-22 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
UY37957A (en) | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
BR112020008833A2 (en) | 2017-11-02 | 2020-10-20 | Calico Life Sciences Llc | modulators of the integrated stress pathway |
WO2019090272A1 (en) | 2017-11-06 | 2019-05-09 | Flx Bio, Inc. | Chemokine receptor modulators for treatment of epstein barr virus positive cancer |
KR20200096941A (en) | 2017-12-07 | 2020-08-14 | 앰플릭스 파마슈티컬스, 인크. | Heterocycle-substituted pyridine derivatives antifungal agents |
WO2019126037A1 (en) | 2017-12-19 | 2019-06-27 | City Of Hope | Modified tracrrnas grnas, and uses thereof |
US11311542B2 (en) | 2018-01-16 | 2022-04-26 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin dependent kinase 7 (CDK7) |
US11918592B2 (en) | 2018-01-16 | 2024-03-05 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin dependent kinase 7 (CDK7) |
WO2019147862A1 (en) | 2018-01-26 | 2019-08-01 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
KR20200143376A (en) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | Substituted imidazopyridines and uses thereof as plasma kallikrein inhibitors |
MX2020011344A (en) | 2018-04-27 | 2021-02-09 | Spruce Biosciences Inc | Methods for treating testicular and ovarian adrenal rest tumors. |
CN112368289B (en) | 2018-05-01 | 2024-02-20 | 锐新医药公司 | C26-linked rapamycin analogues as MTOR inhibitors |
WO2019212990A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
US11931345B2 (en) | 2018-05-04 | 2024-03-19 | Cirius Therapeutics, Inc. | Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases |
JP2021527051A (en) | 2018-06-05 | 2021-10-11 | ラプト・セラピューティクス・インコーポレイテッド | Pyrazolo-pyrimidine-amino-cycloalkyl compounds and their therapeutic use |
PE20210372A1 (en) | 2018-06-21 | 2021-02-26 | Abbvie Inc | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND THEIR METHODS OF USE |
KR20210023984A (en) | 2018-06-25 | 2021-03-04 | 앰플릭스 파마슈티컬스, 인크. | Pyridine derivatives substituted with heterocyclic rings and amino groups |
CN112867503A (en) | 2018-08-24 | 2021-05-28 | 希望之城 | Masked cytokine conjugates |
TWI771621B (en) | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | Prodrug modulators of the integrated stress pathway |
BR112021008128A2 (en) | 2018-11-01 | 2021-08-03 | Lynk Pharmaceuticals Co. Ltd. | tricyclic janus kinase 1 inhibitors, and compositions and methods thereof |
TW202100515A (en) | 2019-03-14 | 2021-01-01 | 美商嘉來克生命科學有限責任公司 | Protein tyrosine phosphatase inhibitors and methods of use thereof |
KR20220016468A (en) | 2019-04-30 | 2022-02-09 | 칼리코 라이프 사이언시스 엘엘씨 | Substituted cycloalkyls as modulators of the integrative stress pathway |
WO2020232274A1 (en) | 2019-05-15 | 2020-11-19 | Bexson Biomedical, Inc. | Ketamine formulation for subcutaneous injection |
WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
JP2022548696A (en) | 2019-09-18 | 2022-11-21 | 武田薬品工業株式会社 | Plasma kallikrein inhibitors and uses thereof |
TW202124445A (en) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | Nkg2d fusion proteins and uses thereof |
CA3158521A1 (en) | 2019-11-13 | 2021-05-20 | Rapt Therapeutics, Inc. | Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof |
EP4077291A1 (en) | 2019-12-18 | 2022-10-26 | Calico Life Sciences LLC | Protein tyrosine phosphatase inhibitors and methods of use thereof |
CN115667217A (en) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | Deuterated tryptamine derivatives and methods of use |
AU2021328671A1 (en) | 2020-08-18 | 2023-02-16 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
WO2022094409A1 (en) | 2020-11-02 | 2022-05-05 | Trethera Corporation | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof |
JP2023551145A (en) | 2020-11-18 | 2023-12-07 | ベクソン バイオメディカル,インク. | Complexing agent salt formulations of pharmaceutical compounds |
WO2022133237A2 (en) | 2020-12-18 | 2022-06-23 | Cornell University | Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak |
US11918582B2 (en) | 2021-03-15 | 2024-03-05 | Rapt Therapeutics, Inc. | Pyrazole pyrimidine compounds and uses thereof |
EP4308228A1 (en) | 2021-03-17 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors |
KR20240004296A (en) | 2021-03-17 | 2024-01-11 | 다께다 파머수티컬 컴패니 리미티드 | Heteroaryl inhibitor of plasma kallikrein |
JP2024512497A (en) | 2021-03-17 | 2024-03-19 | 武田薬品工業株式会社 | Inhibitor of plasma kallikrein |
JP2024510502A (en) | 2021-03-17 | 2024-03-07 | 武田薬品工業株式会社 | Imidazopyridinyl inhibitor of plasma kallikrein |
CN117355523A (en) | 2021-03-17 | 2024-01-05 | 武田药品工业株式会社 | Polycyclic inhibitors of plasma kallikrein |
WO2023156450A1 (en) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
WO2023156453A1 (en) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
US20230322741A1 (en) | 2022-04-06 | 2023-10-12 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3867519A (en) * | 1972-04-27 | 1975-02-18 | Alza Corp | Bioerodible drug delivery device |
US3962414A (en) * | 1972-04-27 | 1976-06-08 | Alza Corporation | Structured bioerodible drug delivery device |
US3987163A (en) * | 1973-07-27 | 1976-10-19 | Burton, Parsons And Company, Inc. | Polystyrene sulfonate containing opthalmic solutions |
US4207890A (en) * | 1977-01-04 | 1980-06-17 | Mcneilab, Inc. | Drug-dispensing device and method |
US4127674A (en) * | 1977-03-21 | 1978-11-28 | Allergan Pharmaceuticals, Inc. | Method of treatment for glaucoma |
US4271143A (en) * | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
US4407792A (en) * | 1979-05-09 | 1983-10-04 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
US4521414A (en) * | 1981-06-18 | 1985-06-04 | The Texas A&M University System | Ophthalmic compositions and their use for treating elevated intraocular pressure and glaucoma |
JPS5858146A (en) * | 1981-10-05 | 1983-04-06 | Tanabe Seiyaku Co Ltd | Microcapsule with fast releasability and preparation thereof |
NZ219925A (en) * | 1986-07-30 | 1989-06-28 | Pennwalt Corp | Polymer-treated sulphonic acid cationic exchange resin particles |
-
1988
- 1988-02-05 US US07/154,514 patent/US4911920A/en not_active Expired - Lifetime
-
1989
- 1989-11-30 AU AU45753/89A patent/AU621692B2/en not_active Expired
- 1989-12-01 CA CA002004468A patent/CA2004468C/en not_active Expired - Lifetime
- 1989-12-01 DE DE68913979T patent/DE68913979T2/en not_active Expired - Lifetime
- 1989-12-01 EP EP89312590A patent/EP0429732B1/en not_active Expired - Lifetime
- 1989-12-01 IL IL9252789A patent/IL92527A/en not_active IP Right Cessation
-
1995
- 1995-02-27 US US08/396,284 patent/US5635172A/en not_active Expired - Lifetime
- 1995-08-24 HK HK135695A patent/HK135695A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU4575389A (en) | 1991-08-01 |
DE68913979T2 (en) | 1994-09-22 |
HK135695A (en) | 1995-09-01 |
US4911920A (en) | 1990-03-27 |
AU621692B2 (en) | 1992-03-19 |
EP0429732A1 (en) | 1991-06-05 |
DE68913979D1 (en) | 1994-04-21 |
IL92527A (en) | 1994-02-27 |
EP0429732B1 (en) | 1994-03-16 |
US5635172A (en) | 1997-06-03 |
CA2004468A1 (en) | 1991-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2004468C (en) | Sustained release, comfort formulation for glaucoma therapy | |
AU761785B2 (en) | Sustained release, and comfortable ophthalmic composition and method for ocular therapy | |
EP0752847B1 (en) | Ophthalmic composition with decreased viscosity | |
US5480900A (en) | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma | |
US5093126A (en) | Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer | |
EP0755246B1 (en) | Ophthalmic composition containing an ion sensitive, hydrophilic polymer and an inorganic salt in a ratio which gives low viscosity | |
CA2104917C (en) | Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions | |
US5182102A (en) | Anti-glaucoma compositions | |
JP2594877B2 (en) | Eye drop composition with improved antibacterial activity | |
WO1993017664A1 (en) | Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions | |
US6258350B1 (en) | Sustained release ophthalmic formulation | |
US5554367A (en) | Compositions for treatment of glaucoma | |
US5932572A (en) | Topical anti-glaucoma compositions | |
EP0625903B1 (en) | Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers | |
NZ231614A (en) | Ophthalmic composition for controlling intraocular pressure | |
JPH0725698B2 (en) | Formulation for the treatment of glaucoma with sustained release and comfortable application | |
KR950013746B1 (en) | Pharmacentical composition for ophtalmic use | |
DK173315B1 (en) | Delayed-release preparation for treating glaucoma | |
JP2003509474A (en) | Use of fatty acid / amino acid soap to enhance the antimicrobial effect of topical pharmaceutical compositions | |
MXPA01003098A (en) | Sustained release, and comfortable ophthalmic composition and method for ocular therapy | |
Xu et al. | Uptake of amino acids by toxic microcystis aeruginosa PCC 7820 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |